The University of Chicago Header Logo

Connection

Piyush Agarwal to Urinary Bladder Neoplasms

Back to Details
This is a "connection" page, showing publications Piyush Agarwal has written about Urinary Bladder Neoplasms.
Piyush Agarwal
Connection Strength
9.719
Urinary Bladder Neoplasms
  1. Trends in the use of immediate postoperative intravesical chemotherapy following transurethral resection of bladder tumors. Urol Oncol. 2025 Jan; 43(1):62.e7-62.e13.
    View in: PubMed
    Score: 0.716
  2. The impact of metabolic syndrome on short term radical cystectomy complications. Urol Oncol. 2024 Dec; 42(12):450.e23-450.e28.
    View in: PubMed
    Score: 0.702
  3. A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of urothelial cancer. Urol Oncol. 2021 09; 39(9):528-547.
    View in: PubMed
    Score: 0.572
  4. Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT). Sci Rep. 2019 02 14; 9(1):2084.
    View in: PubMed
    Score: 0.483
  5. Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience. Diagn Interv Radiol. 2018 Sep; 24(5):316-320.
    View in: PubMed
    Score: 0.468
  6. Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database. Int Urol Nephrol. 2018 Feb; 50(2):257-262.
    View in: PubMed
    Score: 0.446
  7. Editorial Comment. J Urol. 2018 02; 199(2):414-415.
    View in: PubMed
    Score: 0.442
  8. Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M. Cell Mol Life Sci. 2018 03; 75(5):939-963.
    View in: PubMed
    Score: 0.441
  9. Current clinical trials in non-muscle invasive bladder cancer. Urol Oncol. 2017 08; 35(8):516-527.
    View in: PubMed
    Score: 0.434
  10. Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. Mol Cancer Ther. 2017 10; 16(10):2201-2214.
    View in: PubMed
    Score: 0.430
  11. Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. Sci Rep. 2017 03 15; 7(1):201.
    View in: PubMed
    Score: 0.423
  12. Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma. Curr Opin Urol. 2015 Sep; 25(5):468-75.
    View in: PubMed
    Score: 0.380
  13. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol. 2008 Feb; 26(1):39-44.
    View in: PubMed
    Score: 0.223
  14. Emerging drugs for targeted therapy of bladder cancer. Expert Opin Emerg Drugs. 2007 Sep; 12(3):435-48.
    View in: PubMed
    Score: 0.218
  15. Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis. Urol Oncol. 2024 May; 42(5):121-132.
    View in: PubMed
    Score: 0.171
  16. Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials. Urol Oncol. 2024 Aug; 42(8):223-228.
    View in: PubMed
    Score: 0.170
  17. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
    View in: PubMed
    Score: 0.170
  18. Flat intraurothelial lesions of the urinary bladder-do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice. Mod Pathol. 2022 10; 35(10):1296-1305.
    View in: PubMed
    Score: 0.151
  19. Incidence of Preoperative Antibiotic Use and Its Association with Postoperative Infectious Complications after Radical Cystectomy. Urology. 2022 06; 164:169-177.
    View in: PubMed
    Score: 0.149
  20. Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS One. 2021; 16(7):e0241766.
    View in: PubMed
    Score: 0.143
  21. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492.
    View in: PubMed
    Score: 0.142
  22. Multiresolution Application of Artificial Intelligence in Digital Pathology for Prediction of Positive Lymph Nodes From Primary Tumors in Bladder Cancer. JCO Clin Cancer Inform. 2020 04; 4:367-382.
    View in: PubMed
    Score: 0.131
  23. Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. AJR Am J Roentgenol. 2020 01; 214(1):105-113.
    View in: PubMed
    Score: 0.126
  24. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. J Immunol. 2019 06 15; 202(12):3458-3467.
    View in: PubMed
    Score: 0.122
  25. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World J Urol. 2019 Jan; 37(1):51-60.
    View in: PubMed
    Score: 0.117
  26. Bilateral Ureteroenteric Strictures: A Case of the "Reverse 7". Urology. 2018 Aug; 118:e3-e4.
    View in: PubMed
    Score: 0.114
  27. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clin Epigenetics. 2018; 10:19.
    View in: PubMed
    Score: 0.113
  28. Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robot-assisted radical cystectomy for bladder cancer. BJU Int. 2017 06; 119(6):879-884.
    View in: PubMed
    Score: 0.105
  29. Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. Am J Surg Pathol. 2015 Nov; 39(11):1488-92.
    View in: PubMed
    Score: 0.096
  30. Trimodality therapy in bladder cancer: who, what, and when? Urol Clin North Am. 2015 May; 42(2):169-80, vii.
    View in: PubMed
    Score: 0.093
  31. Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol. 2015 Apr; 33(4):167.e13-20.
    View in: PubMed
    Score: 0.091
  32. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. J Transl Med. 2014 Oct 21; 12:199.
    View in: PubMed
    Score: 0.089
  33. New facial papules in a 66-year-old woman with bladder cancer. J Am Acad Dermatol. 2014 Dec; 71(6):1250-5.
    View in: PubMed
    Score: 0.088
  34. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014 May-Jun; 38(3):80-108.
    View in: PubMed
    Score: 0.087
  35. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014 Jul; 32(5):637-44.
    View in: PubMed
    Score: 0.087
  36. Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int. 2014 May; 113(5b):E28-33.
    View in: PubMed
    Score: 0.087
  37. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014 May; 26(3):305-20.
    View in: PubMed
    Score: 0.087
  38. Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2014 Feb; 65(2):340-7.
    View in: PubMed
    Score: 0.083
  39. Reply from authors re: Manfred P. Wirth, Johannes Huber. What really matters is rarely measured: outcome of routine care and patient-reported outcomes. Eur Urol 2013;64:58-9: robot-assisted versus open radical cystectomy: beating a dead horse. Eur Urol. 2013 Jul; 64(1):60-1.
    View in: PubMed
    Score: 0.080
  40. Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). BJU Int. 2013 Jun; 111(7):1075-80.
    View in: PubMed
    Score: 0.080
  41. Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol. 2013 Jul; 64(1):52-7.
    View in: PubMed
    Score: 0.079
  42. Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int. 2010 Dec; 106(11):1799-804.
    View in: PubMed
    Score: 0.068
  43. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 2009 Jan; 73(1):147-52.
    View in: PubMed
    Score: 0.059
  44. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol. 2008 Jan 01; 26(1):121-6.
    View in: PubMed
    Score: 0.056
  45. Targeted therapies in bladder cancer--an update. Urol Oncol. 2007 Sep-Oct; 25(5):433-8.
    View in: PubMed
    Score: 0.055
  46. The Sunshine Act and oncology: Lessons learned from urology. Semin Oncol. 2017 08; 44(4):265-266.
    View in: PubMed
    Score: 0.027
  47. Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer. Int J Hyperthermia. 2017 11; 33(7):733-740.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.